1
|
Alqurashi RM, Tamim HH, Alsubhi ZD, Alzahrani AA, Tashkandi E. Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases. Cureus 2022; 14:e30652. [DOI: 10.7759/cureus.30652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/24/2022] [Indexed: 11/06/2022] Open
|
2
|
Kunimoto S, Tashima L, Ito K, Hori K. Advanced ovarian cancer that resulted in death from intestinal perforation following tumor lysis syndrome: A case report. Int J Surg Case Rep 2022; 98:107518. [PMID: 35994800 PMCID: PMC9420503 DOI: 10.1016/j.ijscr.2022.107518] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Revised: 08/10/2022] [Accepted: 08/12/2022] [Indexed: 01/20/2023] Open
Abstract
Introduction and importance Case presentation Clinical discussion Conclusion Tumor lysis syndrome (TLS) in solid tumors is rare, but predictable to an extent. TLS risk should be evaluated and precautions taken. Chemotherapy-related intestinal perforation is still a risk even after recovering from TLS.
Collapse
Affiliation(s)
- Saki Kunimoto
- Department of Obstetrics & Gynecology, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki City, Hyogo 660-8511, Japan.
| | - Lena Tashima
- Department of Obstetrics & Gynecology, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki City, Hyogo 660-8511, Japan
| | - Kimihiko Ito
- Department of Obstetrics & Gynecology, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki City, Hyogo 660-8511, Japan
| | - Kensuke Hori
- Department of Obstetrics & Gynecology, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki City, Hyogo 660-8511, Japan
| |
Collapse
|
3
|
Schiff JP, Spraker MB, Duriseti S, Shaikh S, Murad HF, Mutch DG, Robinson CG, Kavanaugh J, Lin AJ. Tumor Lysis Syndrome in a Patient With Metastatic Endometrial Cancer Treated With Lattice Stereotactic Body Radiation Therapy. Adv Radiat Oncol 2021; 7:100797. [PMID: 34761139 PMCID: PMC8567179 DOI: 10.1016/j.adro.2021.100797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 08/06/2021] [Accepted: 08/11/2021] [Indexed: 11/24/2022] Open
Affiliation(s)
| | | | | | | | | | - David G Mutch
- Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, St Louis, Missouri
| | | | | | | |
Collapse
|
4
|
Castellano T, Bulard BA, Staley A, Moore KN. Tumor lysis syndrome in gynecologic cancers: An uncommon but important diagnosis to recognize. Gynecol Oncol Rep 2019; 30:100514. [PMID: 31788528 PMCID: PMC6880131 DOI: 10.1016/j.gore.2019.100514] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2019] [Revised: 10/28/2019] [Accepted: 11/03/2019] [Indexed: 12/04/2022] Open
Abstract
TLS treated with rasburicase is rare and associated with approximately 5% of gynecologic cancers. TLS is most frequently associated with new diagnosis of high-grade gynecologic malignancies. The most common presenting symptoms of TLS include acute kidney injury and electrolyte derangement. Early recognition and treatment of TLS can rapidly improve uric acid and electrolyte derangements.
Objectives To describe the incidence, treatment and outcomes associated with tumor lysis syndrome (TLS) in women with gynecologic cancer (GOC). Methods A retrospective multi-institutional review of TLS associated with GOC. Women presenting with an elevated serum uric acid managed with intravenous (IV) rasburicase were included. Descriptive statistics of patient demographics, clinical findings, and outcome data was completed. Results From two large academic institutions N = 18 patients were found to meet inclusion criteria from 2008 to 2018, reflecting an approximate 5% incidence of clinically treated TLS associated with GOC in our cohort. Median age was 60 years, a majority were Caucasian (n = 11, 61.1%), median BMI was 36.2. TLS was associated with a high-grade GOC in n = 17 (94.4%) cases. TLS was commonly diagnosed with a new GOC (n = 12, 70.6%) and following receipt of chemotherapy in n = 9 (50.0%) cases. Six (66.7%) patients were treated with paclitaxel or combination, five (55.5%) with a platinum or combination, and two (22.2%) with a CD47 inhibitor. Chief complaints included electrolyte and renal abnormalities (n = 11, 73.3%). Peak serum uric acid, potassium, creatinine and phosphorus levels were 14.1 mg/dL, 5.7 mEq/L, 5.1 mg/dL, and 6.8 mg/dL, respectively. Nine patients received hospice during their admission with 3 (20%) deaths occurring as inpatients. There were 12 deaths with median OS of 16 d (range: 2–87 d). Conclusions Though rare, TLS can be associated with GOC. Early recognition of presenting symptoms, laboratory findings and expedited treatment may help with electrolyte recovery; however, TLS associated with GOC may herald a rapidly deteriorating state with significant associated mortality.
Collapse
Affiliation(s)
- T Castellano
- Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - B A Bulard
- Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - A Staley
- University of North Carolina Hospitals, Chapel Hill, NC, USA
| | - K N Moore
- Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| |
Collapse
|
5
|
Abstract
Tumor lysis syndrome is a constellation of metabolic derangements seen when tumor cells die and release their intracellular contents into the systemic circulation. Hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia may lead to severe organ dysfunction and even death. Tumor lysis syndrome is classically considered a complication of successful cancer treatment, but it can also occur in untreated malignancies characterized by rapid proliferation. In this review, we cover the types of cancers and chemo- and immunotherapies associated with tumor lysis syndrome, the mechanisms by which severe metabolic derangements can develop, and the available treatments.
Collapse
Affiliation(s)
- Krishna Sury
- Section of Nephrology, Department of Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA
| |
Collapse
|
6
|
Shukla DK, Gupta D, Aggarwal A, Kumar D. A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase. Indian J Med Paediatr Oncol 2017; 38:360-362. [PMID: 29200691 PMCID: PMC5686984 DOI: 10.4103/ijmpo.ijmpo_23_16] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Tumor Lysis Syndrome (TLS) commonly occurs in hematological malignancies, but it is very rare in patients with a solid tumor. In cases of solid tumors, TLS usually occurs spontaneously or after the initiation of anticancer therapy, and it has a high mortality rate. This syndrome consists of a constellation of laboratory findings such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia known as laboratory TLS. When clinical complications such as seizures, acute renal failure, and cardiac dysrhythmias occur in patients with laboratory TLS, the syndrome is called clinical TLS. The present case report is sixth in the series and probably the first case report of spontaneous TLS in a newly diagnosed patient of epithelial ovarian cancer and also shows the effectiveness of single dose (1.5 mg) of rasburicase along with adequate hydration to rapidly reverse TLS and also timely initiation of definitive treatment. The patient was then able to complete successfully the planned neoadjuvant chemotherapy and surgery without any long-term sequela.
Collapse
Affiliation(s)
| | - Dinesh Gupta
- Department of Surgical Oncology, Manipal Hospital, Jaipur, Rajasthan, India
| | - Arun Aggarwal
- Department of Radiation Oncology, Adhar Hospital, Hisar, Haryana, India
| | - Deepak Kumar
- Department of Radiation Oncology, OP Jindal Institute of Cancer and Research, Hisar, Haryana, India
| |
Collapse
|
7
|
A Case of Spontaneous Tumor Lysis Syndrome in a Patient with Ovarian Cancer. Case Rep Obstet Gynecol 2015; 2015:461870. [PMID: 26161277 PMCID: PMC4487917 DOI: 10.1155/2015/461870] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Accepted: 06/10/2015] [Indexed: 11/17/2022] Open
Abstract
Tumor lysis syndrome (TLS) is a potentially life-threating complication of tumors or chemotherapy treatment. TLS commonly occurs in hematological malignancies, but it is very rare in patients with a solid tumor. In cases of solid tumors, TLS usually occurs spontaneously and after the initiation of anticancer therapy, and it has a high mortality rate. We present the novel case of a 62-year-old woman with an ovarian tumor who spontaneously developed TLS. Surgical reduction of the tumor mass vastly improved her condition. She showed no sign of tumor recurrence 8 months after treatment. As TLS is life-threatening, successful treatments must be seriously considered.
Collapse
|
8
|
Mirrakhimov AE, Ali AM, Khan M, Barbaryan A. Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature. Rare Tumors 2014; 6:5389. [PMID: 25002953 PMCID: PMC4083673 DOI: 10.4081/rt.2014.5389] [Citation(s) in RCA: 107] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Accepted: 04/08/2014] [Indexed: 12/20/2022] Open
Abstract
Tumor lysis syndrome (TLS) is a potentially deadly complication of tumors or their treatment. This syndrome consists of a constellation of laboratory findings such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, known as laboratory TLS. When clinical complications such as seizures, acute renal failure, and cardiac dysrhythmias occur in patients with laboratory TLS, the syndrome is called clinical TLS. TLS is especially common in patients with hematological malignancies with rapid cellular turnover rates such as acute lymphocytic leukemia and Burkitt lymphoma, but is very rare in patients with solid tumors. Nevertheless, there are multiple reports in the literature on the occurrence of TLS in patients with solid tumors. In this review article, we summarize the current data on the occurrence of TLS in patients with solid tumors. We propose an algorithm of risk stratification and prevention of TLS in patients with solid cancers.
Collapse
|
9
|
Camarata M, Davies R, Copley S, Blagden S. Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer. BMJ Case Rep 2013; 2013:bcr2013009532. [PMID: 23616333 PMCID: PMC3645192 DOI: 10.1136/bcr-2013-009532] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Tumour lysis syndrome is a potentially life-threatening oncological emergency most commonly encountered in patients with rapidly proliferating, treatment-responsive haematological malignancies. It is rarely observed in solid tumours and, to our knowledge, this is the first time that it has been reported in a cancer with an intravascular tumour extension. In this report, we describe a case of a woman who presented with recurrent ovarian cancer and was found to have tumour invading into her vasculature. The patient subsequently developed tumour lysis syndrome after receiving chemotherapy. The case highlights the importance of considering tumour lysis syndrome prophylaxis when treating patients with intravascular involvement from a solid malignancy even if, as in this case, it is a recurrent tumour. Included is a brief review of the literature. We propose that 'intravascular tumour invasion is recognised as an important risk factor for the development of tumour lysis syndrome.
Collapse
Affiliation(s)
| | - Roger Davies
- Intensive Care Unit, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK
| | - Sue Copley
- Imperial College Healthcare NHS Trust, London, UK
| | - Sarah Blagden
- Department of Oncology, Imperial College Healthcare NHS Trust, Hammersmith Hospital Campus, London, UK
| |
Collapse
|
10
|
Firwana BM, Hasan R, Hasan N, Alahdab F, Alnahhas I, Hasan S, Varon J. Tumor lysis syndrome: a systematic review of case series and case reports. Postgrad Med 2012; 124:92-101. [PMID: 22437219 DOI: 10.3810/pgm.2012.03.2540] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Tumor lysis syndrome (TLS) is a clinical condition that is caused by a massive lysis of tumor cells that accumulate very rapidly and disturb hemodynamics. This oncologic emergency requires immediate intervention. Tumor lysis syndrome was first described in the 19th century. Since then, it has become a well-known disease with improved management measures. Tumor lysis syndrome can occur after any type of neoplasm. It is highly associated with rapidly proliferating tumors compared with those that are well demarcated, such as acute lymphoblastic leukemia and high-grade non-Hodgkin lymphoma. Initiation of chemotherapy, radiotherapy, or steroid treatment may trigger TLS, or it may develop spontaneously. The release of massive quantities of intracellular contents may produce hyperkalemia, hyperphosphatemia, secondary hypocalcemia, hyperuricemia, and acute renal failure. Prevention and treatment measures include intravenous hydration, use of allopurinol and rasburicase, management of TLS-associated electrolyte abnormalities, and renal replacement therapy; the use of urine alkalinization remains controversial. In this article, we summarize the findings of case series and case reports published over the past 6 years in an effort to help familiarize clinicians better recognize and manage TLS.
Collapse
Affiliation(s)
- Belal M Firwana
- Department of Internal Medicine, University of Missouri, Columbia, USA
| | | | | | | | | | | | | |
Collapse
|
11
|
Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2010; 13:98-107. [PMID: 20849361 DOI: 10.3109/14653249.2010.515582] [Citation(s) in RCA: 316] [Impact Index Per Article: 22.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Natural killer (NK) cells derived from patients with cancer exhibit diminished cytotoxicity compared with NK cells from healthy individuals. We evaluated the tumor response and in vivo expansion of allogeneic NK cells in recurrent ovarian and breast cancer. METHODS Patients underwent a lymphodepleting preparative regimen: fludarabine 25 mg/m(2) × 5 doses, cyclophosphamide 60 mg/kg × 2 doses, and, in seven patients, 200 cGy total body irradiation (TBI) to increase host immune suppression. An NK cell product, from a haplo-identical related donor, was incubated overnight in 1000 U/mL interleukin (IL)-2 prior to infusion. Subcutaneous IL-2 (10 MU) was given three times/week × 6 doses after NK cell infusion to promote expansion, defined as detection of ≥100 donor-derived NK cells/μL blood 14 days after infusion, based on molecular chimerism and flow cytometry. RESULTS Twenty (14 ovarian, 6 breast) patients were enrolled. The median age was 52 (range 30-65) years. Mean NK cell dose was 2.16 × 10(7)cells/kg. Donor DNA was detected 7 days after NK cell infusion in 9/13 (69%) patients without TBI and 6/7 (85%) with TBI. T-regulatory cells (Treg) were elevated at day +14 compared with pre-chemotherapy (P = 0.03). Serum IL-15 levels increased after the preparative regimen (P = <0.001). Patients receiving TBI had delayed hematologic recovery (P = 0.014). One patient who was not evaluable had successful in vivo NK cell expansion. CONCLUSIONS Adoptive transfer of haplo-identical NK cells after lymphodepleting chemotherapy is associated with transient donor chimerism and may be limited by reconstituting recipient Treg cells. Strategies to augment in vivo NK cell persistence and expansion are needed.
Collapse
Affiliation(s)
- Melissa A Geller
- Obstetrics and Gynecology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Godoy H, Kesterson JP, Lele S. Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer. Int J Gynaecol Obstet 2010; 109:254. [PMID: 20362289 DOI: 10.1016/j.ijgo.2010.02.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2009] [Revised: 02/07/2010] [Accepted: 02/19/2010] [Indexed: 11/17/2022]
Affiliation(s)
- Heidi Godoy
- Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 1426, USA
| | | | | |
Collapse
|